Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on June 30, 2022, that its Compensation Committee granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. These options total 21,000 shares, with an exercise price of $0.96 per share, aligning with the closing price on that date. The options will vest over four years, and this issuance is in compliance with Nasdaq Listing Rule 5635(c)(4). X4 focuses on developing CXCR4-targeted small molecule therapies, including its lead candidate mavorixafor for immune system dysfunction.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a private investment in public equity (PIPE) financing, agreeing to sell 50,925,365 shares of common stock and warrants, with expected gross proceeds of approximately $55 million. The financing is set to close around July 6, 2022. Concurrently, X4 amended its loan agreement with Hercules Capital to extend the interest-only period by up to 12 months, potentially reducing cash burn by $20 million. Funds will support clinical development of mavorixafor and general corporate purposes. The PIPE includes participation from several institutional investors.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) announced it will present research data on its lead drug candidate, mavorixafor, at the European Hematology Association congress in Vienna, June 9-17, 2022. Mavorixafor is an oral CXCR4 antagonist undergoing clinical trials for WHIM syndrome, chronic neutropenia, and Waldenström’s macroglobulinemia. Key findings include 17 new CXCR4 genetic variants related to WHIM, a new cell-based model for studying WHIM, and evidence of mavorixafor’s potential in enhancing B-cell therapies for WM.
X4 Pharmaceuticals (Nasdaq: XFOR) reported its Q1 2022 financial results, highlighting a net loss of $22 million, up from $18.7 million in Q1 2021. Cash and equivalents stood at $67.7 million, sufficient to fund operations through Q4 2022. The company anticipates top-line data from its pivotal 4WHIM Phase 3 trial for WHIM syndrome by year-end, alongside ongoing updates from a chronic neutropenia Phase 1b study and a fully enrolled Waldenström's Macroglobulinemia Phase 1b study. R&D expenses increased to $14.1 million, influenced by ongoing trials and initiatives to enhance disease awareness.
X4 Pharmaceuticals (Nasdaq: XFOR) will announce its first quarter financial results for the period ending March 31, 2022, on May 12, 2022. The company will also share business highlights during a conference call at 8:30 a.m. ET on the same day. Investors can join the call by dialing (866) 721-7655 in the U.S. or (409) 216-0009 internationally. X4’s lead candidate, mavorixafor, is being developed to treat immune system diseases, with ongoing clinical trials demonstrating its potential efficacy in conditions such as WHIM syndrome and certain cancers.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. On April 29, 2022, the Compensation Committee granted options to purchase 21,000 shares of common stock at an exercise price of $1.29 per share. The options will vest over four years, starting with 25% after 12 months. X4 focuses on developing novel therapies for immune system disorders, with its lead candidate mavorixafor in Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a poster presentation at the AACR Annual Meeting 2022 in New Orleans, from April 8-12, 2022. The poster, titled Mavorixafor Enhances Efficacy of Bruton’s Tyrosine Kinase Inhibitors, will detail mavorixafor’s role in overcoming bone marrow stroma protections in Waldenström’s macroglobulinemia. Presenter Chi Nguyen, Ph.D., will share insights on April 10, 1:30-5 pm CT. Mavorixafor, a leading small molecule therapy, targets CXCR4 and is critical to treating immune system diseases, including WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced presentations at two upcoming virtual healthcare conferences. The company will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:45 PM ET. Additionally, a fireside chat will occur at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference on April 14, 2022, from 10:30 AM to 11:00 AM ET. Both events will be available for live streaming and archived on X4's website for 90 days.
X4 Pharmaceuticals (NASDAQ: XFOR) announced on March 31, 2022, that its Board's Compensation Committee issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The inducement awards include options for 92,850 shares of common stock at an exercise price of $1.75, equivalent to the stock's closing price on the grant date. These options vest over four years, contingent on ongoing employment. X4 specializes in CXCR4-targeted therapies aimed at treating immune system disorders, with its lead candidate being mavorixafor, currently in clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its fourth-quarter and annual financial results for 2021, reporting a net loss of $30.2 million for Q4 and $88.7 million for the year. Despite increased losses compared to 2020, the company completed enrollment in its pivotal 4WHIM Phase 3 trial for mavorixafor, targeting WHIM syndrome, with top-line data expected in 4Q22. Ongoing trials for chronic neutropenia and Waldenström’s macroglobulinemia are on track, with additional data anticipated in 2022. As of December 31, 2021, X4 had $83.1 million in cash, projected to fund operations into late 2022.